Lupus Nephritis Management: Monitoring Strategies and Long-Term Study Results

Panelists discuss the differences in efficacy and safety profiles between belimumab and voclosporin for lupus nephritis (LN) and how payers are evaluating their value, including considerations of cost-effectiveness in LN management.

EP: 1.Understanding the Clinical Burden and Prevalence of Lupus Nephritis

EP: 2.Cost Drivers in Lupus Nephritis

EP: 3.Urgency to Treat in Lupus Nephritis: Goals of Therapy and Early Diagnosis Strategies

EP: 4.Guideline Updates in Lupus Nephritis: Impacts on Clinical Decision-Making

EP: 5.Tailoring Lupus Nephritis Treatment: Key Considerations and Specialist Approaches

EP: 6.Belimumab and Voclosporin: Clinical Insights and Payer Evaluations in Lupus Nephritis

EP: 7.Improving Access to Lupus Nephritis Treatment: Strategies and Resources

Now Viewing

EP: 8.Lupus Nephritis Management: Monitoring Strategies and Long-Term Study Results

EP: 9.Collaborating for Better Care: Healthcare Providers and Payers in Lupus Nephritis

EP: 10.From Guidelines to Practice: Advancing Lupus Nephritis Treatment

EP: 11.Looking Ahead: Anticipating Changes in Lupus Guidelines and Clinical Practice

• How do you monitor patients with lupus nephritis for disease progression and treatment response? (Dr. Larranaga)
• Three-year follow-up results of voclosporin from the AURORA-2 study were published earlier this year. What is the value of long-term follow-up data such as these in lupus nephritis? (Dr. Wells)

Related Videos